<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067415</url>
  </required_header>
  <id_info>
    <org_study_id>171GLC16020</org_study_id>
    <nct_id>NCT03067415</nct_id>
  </id_info>
  <brief_title>Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily</brief_title>
  <official_title>A Multi Center, Randomized, Double-blind, Parallel Design, Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily in Primary Open Angle Glaucoma or Ocular Hypertension Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exploratory trial to evaluate the efficacy and safety of D565H twice daily versus D565 once
      daily.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multi center, Randomized, Double-blind, Parallel design, Exploratory trial to evaluate the
      efficacy and safety of D565H twice daily versus D565 once daily in primary open angle
      glaucoma or ocular hypertension patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">September 10, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean intraocular pressure at 4 weeks compared to baseline</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Mean baseline intraocular pressure change Mean intraocular pressure change after 4 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean intraocular pressure at 2 weeks compared to baseline</measure>
    <time_frame>Baseline, 2 weeks</time_frame>
    <description>Mean baseline intraocular pressure change Mean intraocular pressure change after 2 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in intraocular pressure by measurement time</measure>
    <time_frame>2 weeks, 4 weeks</time_frame>
    <description>IOP variation by measurement time</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety assessed by the incidence of adverse event, History, Medication</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Adverse events, history, medications, signs of vitality, physical examination, etc.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Glaucoma, Primary Open Angle</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>D565H(Latanoprost 25㎍/㎖)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D565H(Latanoprost 25㎍/㎖)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D565(Latanoprost 50㎍/㎖)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>D565(Latanoprost 50㎍/㎖)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D565H(Latanoprost 25㎍/㎖)</intervention_name>
    <description>D565H twice daily</description>
    <arm_group_label>D565H(Latanoprost 25㎍/㎖)</arm_group_label>
    <arm_group_label>D565(Latanoprost 50㎍/㎖)</arm_group_label>
    <other_name>Arm A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D565(Latanoprost 50㎍/㎖)</intervention_name>
    <description>D565 once daily</description>
    <arm_group_label>D565H(Latanoprost 25㎍/㎖)</arm_group_label>
    <arm_group_label>D565(Latanoprost 50㎍/㎖)</arm_group_label>
    <other_name>Arm B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. More than the age of 19 years old

          2. Subjects who has primary Open-Angle Glaucoma or Ocular Hypertension

          3. Subjects who sign on an informed consent form willingly

        Exclusion Criteria:

          1. Subjects with IOP(Intraocular Pressure) measured at Visit 1 and Visit 2(AM 09:00)
             above 35 mmHg at more than one eye

          2. Subjects with a maximum corrected visual acuity of less or than 0.3 in the selected
             evaluation eye at visit 2

          3. Subjects who were diagnosed as below with monocular or both eye

               -  Acute or Chronic Closed-Angle Glaucoma

               -  Secondary Glaucoma

               -  Pseudoexfoliation Glaucoma

               -  Neovascular Glaucoma

               -  aphakia

               -  phacocyst capsular torn intraocular lens

          4. Subjects with significant eye symptoms/signs(Abscesses, diplopia) or severe visual
             field impairment(Mean Deviation -25dB or more)

          5. Subjects with severe dry eye syndrome or progressive retinal disease(Retinal
             degeneration, Diabetic retinopathy, Retinal detachment, Macular edema)

          6. Subjects with inflammatory/infectious eye disease and active eye disease within the
             last 3 months

          7. Subjects who have medical history following

               -  Glaucoma surgery

               -  Subjects with significant history of ocular trauma during the last 6 months, or
                  who underwent surgical ophthalmic surgery

               -  Subjects who received topical or systemic steroids within the last 6 months

          8. Subjects who wore need to wear contact lenses during the study

          9. Subjects who have drug interaction with the investigational product, have a
             significant effect on the intraocular pressure, or who may have an effect on the
             clinical trial results

         10. Subjects with known hypersensitivity to investigational product

         11. Women who are nursing, pregnant or planning pregnancy during the study

         12. Subjects with bronchial asthma or history

         13. Subjects who have received any other investigational product within 1 month prior to
             the first dosing

         14. Impossible subjects who participate in clinical trial by investigator's decision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KiHo Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hosipital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KiHo Park</last_name>
    <phone>82-10-3458-3172</phone>
    <email>kihopark@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hosipital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KiHo Park, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma, Primary Open Angle</keyword>
  <keyword>Ocular hypertension</keyword>
  <keyword>CKD-351</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

